The pharmaceutical company is urgently seeking additional funding to avoid being placed into administration, as it has limited working capital and is yet to receive requested funds from its credit facility.
The pharmaceutical company has decided to terminate a credit facility it had previously announced, citing no longer needing the funds.
The pharmaceutical company is facing a funding crisis, with uncertainty around securing additional financing to continue operations.
The pharmaceutical company plans to delist from the AIM market, citing a desire to reduce costs and access capital more easily as an unlisted firm. However, the move raises concerns over governance and shareholder value.
The pharmaceutical company faces a delay in receiving new funding, but is taking steps to ensure it has sufficient working capital.
The pharmaceutical company has secured a new £1.95 million committed credit facility to support its operations and growth.
The pharmaceutical company received additional financing and a tax credit, but the news does not appear to significantly impact its prospects.
The pharmaceutical company provides an update on its financial position, including a pending payment and exploration of alternative lending facilities.
The pharmaceutical company has secured a strategic collaboration that will boost its production capacity and help it fulfill existing contracts, positioning it to capitalize on growing European demand for medicinal cannabis.
The pharmaceutical company secures additional funding to maintain operations, but details on its financial performance and growth prospects are limited.